Lymphoma Clinical Trials in Houston

Showing 101-120 of 533 trials

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

NCT02264613

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.

Solid TumorLymphomaPeripheral T-Cell Lymphoma

Aileron Therapeutics, Inc.142 participantsStarted Oct 2014

Birmingham, Alabama, United States • Duarte, California, United States • Denver, Colorado, United States +10 more locations

COMPLETEDPhase 2< 1 mile

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT03210662

This phase II trial studies how well pembrolizumab and external beam radiation therapy work in treating patients with non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and external beam radiation therapy may work better in treating patients with non-Hodgkin lymphoma than pembrolizumab alone.

Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Aggressive Non-Hodgkin LymphomaRecurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma+8 more

M.D. Anderson Cancer Center17 participantsStarted Feb 2018

Houston, Texas, United States

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma Trials in Other Cities

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Other Conditions in Houston